Division of Rheumatology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
Division of Rheumatology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.
Arthritis Care Res (Hoboken). 2023 Jul;75(7):1452-1461. doi: 10.1002/acr.25016. Epub 2023 Feb 12.
Primary myocardial involvement is an important cause of death in systemic sclerosis (SSc). Subclinical diastolic/systolic heart dysfunction is recognized; however, whether this indicates a subsequent increased risk of clinically overt heart failure (HF) remains largely unknown. We aimed to investigate the risk of clinically overt HF in a large, unselected SSc cohort.
This matched, retrospective cohort study was conducted using a nationwide insurance database in Taiwan. Incident SSc patients with no history of HF were identified, and non-SSc comparison groups were selected and matched to the SSc groups by age, sex, and cohort entry time. The cumulative HF incidence was estimated using the Kaplan-Meier method. Multivariable Cox proportional hazards regression was used to calculate adjusted hazard ratios (HRs) for HF hospitalization.
A total of 1,830 SSc patients and 27,981 controls were identified. The cumulative incidence of hospitalized HF at 3, 5, and 10 years among patients with SSc were 3.5%, 5.3%, and 9.7%, respectively. Compared with non-SSc individuals, SSc patients had an increased risk of HF (adjusted HR 3.26 [95% confidence interval (95% CI) 2.49-4.28]). Subgroup analyses revealed that the impact of SSc on the occurrence of HF was greater among patients ages <50 years than those ages ≥50 years (HR 7.8 [95% CI 4.03-15.1] versus HR 2.78 [95% CI 2.06-3.76]).
SSc is associated with a markedly higher risk of clinically evident HF and not asymptomatic ventricular dysfunction alone. These findings provide real-world evidence suggesting the use of appropriate screening strategies to detect these lethal complications early in SSc.
原发性心肌受累是系统性硬化症(SSc)患者死亡的重要原因。目前已经认识到亚临床舒张/收缩期心脏功能障碍,但尚不清楚这是否预示着随后发生临床显性心力衰竭(HF)的风险增加。我们旨在调查大型未选择 SSc 队列中临床显性 HF 的风险。
本研究使用台湾全国性保险数据库进行了匹配的回顾性队列研究。识别出无 HF 病史的新发 SSc 患者,并选择非 SSc 对照组,并按年龄、性别和队列入组时间与 SSc 组进行匹配。采用 Kaplan-Meier 法估计 HF 的累积发病率。采用多变量 Cox 比例风险回归计算 HF 住院的调整后危险比(HR)。
共确定了 1830 名 SSc 患者和 27981 名对照者。SSc 患者 3、5 和 10 年的 HF 住院累积发生率分别为 3.5%、5.3%和 9.7%。与非 SSc 个体相比,SSc 患者 HF 风险增加(调整 HR 3.26[95%置信区间(95%CI)2.49-4.28])。亚组分析显示,SSc 对年龄<50 岁患者发生 HF 的影响大于年龄≥50 岁患者(HR 7.8[95%CI 4.03-15.1]与 HR 2.78[95%CI 2.06-3.76])。
SSc 与明显更高的临床显性 HF 风险相关,而不仅仅是无症状性心室功能障碍。这些发现提供了真实世界的证据,表明应使用适当的筛查策略来早期发现 SSc 中的这些致命并发症。